DB:2RW

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions.


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has ReWalk Robotics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2RW's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-2.5%

2RW

0.8%

DE Medical Equipment

3.2%

DE Market


1 Year Return

-61.6%

2RW

40.7%

DE Medical Equipment

0.01%

DE Market

Return vs Industry: 2RW underperformed the German Medical Equipment industry which returned 38.3% over the past year.

Return vs Market: 2RW underperformed the German Market which returned -0.1% over the past year.


Shareholder returns

2RWIndustryMarket
7 Day-2.5%0.8%3.2%
30 Day19.5%11.4%4.7%
90 Day81.7%27.7%-0.9%
1 Year-61.6%-61.6%42.4%40.7%1.7%0.01%
3 Year-95.7%-95.7%124.2%120.1%-6.8%-14.0%
5 Year-99.6%-99.6%276.4%263.0%3.9%-9.5%

Price Volatility Vs. Market

How volatile is ReWalk Robotics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ReWalk Robotics undervalued compared to its fair value and its price relative to the market?

0.86x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 2RW's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 2RW's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 2RW is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: 2RW is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2RW's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2RW is good value based on its PB Ratio (0.9x) compared to the DE Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is ReWalk Robotics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

36.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2RW is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2RW is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2RW is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2RW's revenue (32.9% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: 2RW's revenue (32.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2RW's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ReWalk Robotics performed over the past 5 years?

6.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 2RW is currently unprofitable.

Growing Profit Margin: 2RW is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 2RW is unprofitable, but has reduced losses over the past 5 years at a rate of 6.9% per year.

Accelerating Growth: Unable to compare 2RW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2RW is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.2%).


Return on Equity

High ROE: 2RW has a negative Return on Equity (-144.26%), as it is currently unprofitable.


Next Steps

Financial Health

How is ReWalk Robotics's financial position?


Financial Position Analysis

Short Term Liabilities: 2RW's short term assets ($21.1M) exceed its short term liabilities ($10.2M).

Long Term Liabilities: 2RW's short term assets ($21.1M) exceed its long term liabilities ($3.4M).


Debt to Equity History and Analysis

Debt Level: 2RW's debt to equity ratio (64.6%) is considered high.

Reducing Debt: Insufficient data to determine if 2RW's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2RW has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 2RW has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 1% each year.


Next Steps

Dividend

What is ReWalk Robotics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2RW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2RW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2RW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2RW's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2RW's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Larry Jasinski (62yo)

8.25yrs

Tenure

US$553,512

Compensation

Mr. Lawrence J. Jasinski, also known as Larry, BS, MBA has been the Chief Executive Officer at ReWalk Robotics Ltd. (formerly Argo Medical Technologies) since February 12, 2012. From 2005 to 2012, Mr. Jasi ...


CEO Compensation Analysis

Compensation vs Market: Larry's total compensation ($USD553.51K) is about average for companies of similar size in the German market ($USD430.63K).

Compensation vs Earnings: Larry's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Lawrence Jasinski
CEO & Director8.25yrsUS$553.51k0.033% $4.9k
Ori Gon
Chief Financial Officer2.25yrsUS$276.84k0.0049% $722.2
Miri Pariente
Vice President of QA & Operations3.25yrsno datano data
Andy Dolan
Vice President of Marketing & Reimbursement2.17yrsno datano data
Judy Kula
Vice President of Customer Service2.17yrsno datano data
Ami Kraft
Executive Advisor to the CEO2.58yrsUS$310.00kno data

2.4yrs

Average Tenure

52yo

Average Age

Experienced Management: 2RW's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Lawrence Jasinski
CEO & Director8.25yrsUS$553.51k0.033% $4.9k
Wayne Weisman
Independent Director11.33yrsUS$25.00k0.045% $6.6k
John Poduska
Independent Director5.67yrsUS$73.95k0.045% $6.6k
Jeffrey Dykan
Independent Chairman of the Board11.33yrsUS$25.00k0.017% $2.5k
Yohanan Engelhardt
Independent Director2yrsUS$70.31k0.044% $6.6k
Aryeh Dan
Independent Director7.33yrsUS$25.00k0.045% $6.6k
Yasushi Ichiki
Independent Director6.33yrsUS$25.00k0.045% $6.6k

7.3yrs

Average Tenure

61yo

Average Age

Experienced Board: 2RW's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 186.3%.


Top Shareholders

Company Information

ReWalk Robotics Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ReWalk Robotics Ltd.
  • Ticker: 2RW
  • Exchange: DB
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$16.296m
  • Listing Market Cap: US$14.739m
  • Shares outstanding: 12.93m
  • Website: https://www.rewalk.com

Number of Employees


Location

  • ReWalk Robotics Ltd.
  • 3 Hatnufa Street
  • 6th Floor
  • Yokneam Illit
  • 2069203
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RWLKNasdaqCM (Nasdaq Capital Market)YesOrdinary SharesUSUSDSep 2014
2RWDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2014

Biography

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions. It offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. The company is also developing ReWalk Restore, a soft suit exoskeleton for rehabilitation of individuals suffering from a stroke. It markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokneam Ilit, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/28 23:49
End of Day Share Price2020/05/28 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.